Views & Analysis 'Free' pricing in the UK: the influence of NICE and NHS Engl... UK drug pricing: just how free is free pricing, these days?
Views & Analysis NICE numbers: trends in recommendations should prompt a revi... Should there be a different review of NICE as part of a successor PPRS?
Views & Analysis Has the UK been best place in the world to invest in life sc... How has the UK compared to its European peers in terms of supporting growth and innovation in the pharmaceutical sector? And with a renegotiation of the PPRS pricing deal imminent, Leela
Views & Analysis Could the PPRS support a changing growth and innovation agen... Has the PPRS delivered on the aim to support the government’s growth and innovation agenda?
Views & Analysis Bureaucracy and duplication: the reality of the PPRS Has the PPRS delivered on the aim of reducing bureaucracy and duplication?
Views & Analysis Improved access? The reality of the PPRS Keeping the UK branded medicines bill within affordable limits - has PPRS delivered?
News After setback, Rhythm gets good news on Imcivree from FDA Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
